Malaria Clinical Trial
Official title:
An Open-label Three Arm Trial of the Efficacy and Safety of Chlorproguanil / Dapsone (Lapdap) Compared With Chloroquine and Sulfadoxine / Pyrimethamine for the Treatment of Vivax Malaria in Pakistan and Afghanistan
To determine whether two cheap antifolates (chlorproguanil-dapsone and sulfadoxine-pyrimethamine) which work against falciparum malaria in this region are sufficiently effective against vivax malaria to be deployed in areas where diagnosis is poor and the burden of malaria is high, a randomised controlled trial of the three drugs is being undertaken comparing their efficacy in treating malaria.
Objectives:
Primary:
To evaluate the comparative efficacy of chlorproguanil / dapsone with
sulfadoxine-pyrimethamine for the treatment of vivax malaria in Pakistan and eastern
Afghanistan.
Secondary:
- To compare the efficacy of chlorproguanil-dapsone and sulfadoxine-pyrimethamine with
chloroquine
- To evaluate the safety profile of chlorproguanil / dapsone in south Asians from this
region when used for the treatment of vivax malaria.
- To evaluate the effect of chlorproguanil / dapsone on gametocyte clearance rates.
- To evaluate the effect of chlorproguanil / dapsone on subsequent relapse due to vivax
malaria.
Study Population:
750 P.vivax positive individuals recruited from the Malaria Reference Centre in Jalalabad,
Afghanistan and at health facilities in Afghan refugee camps in North West Frontier Province
(NWFP), Pakistan supervised by HealthNet International
Efficacy Parameters :
Primary Efficacy Variable:
• Day 14 slide clearance rate (complete clearance of parasites), assessed by microscopists
who are blind to treatment allocation. Slides will be double read.
Secondary Efficacy Variables
- Day 28 slide clearance rate defined as the number of treated patients with clearance of
parasitaemia within 14 days of starting treatment, without subsequent recrudescence up
to day 28.
- Day 14 clinical failure rate (presence of symptoms of malaria in the presence of
parasitaemia).
- Day 28 clinical failure rate.
- Adverse events.
- Haemoglobin level increased by at least 1g/dl by day 14.
- Clearance of gametocytaemia by day 3, 7, and 14.
- Number of subsequent malaria episodes in next 6 months. It is assumed that the
population of each treatment arm is equally likely to be re-infected in this time
scale. Therefore any measurable difference in number of subsequent episodes between
treatment arms will be due to a relapse.
- In G6PD deficient patients the change in mean haemoglobin.
Safety Parameters:
Adverse events and laboratory findings will be monitored in all patients. Regular
haemoglobin to identify haemolysis.
Study design:
Recruitment and administration:
Recruitment and administration of all treatments will be directly observed by the trial
coordinator and trial pharmacist, and/or health unit clinician.
Dosing Schedules:
Chlorproguanil-dapsone (Lapdap): (target doses 2.0 and 2.5 mg/kg respectively) daily for 3
days .
Sulfadoxine - pyrimethamine (SP): (target doses 1.25 and 25.0 mg/kg respectively) once only.
Chloroquine (CQ): (target dose 25mg/kg ) daily for 3 days.
Follow up:
Patients will return to the clinic on days 0, 1, 2, 3, 7, 14, 21 and 28 for supervised
dosing, thick and thin smears, blood spot filter papers, update of clinical record forms,
determination of haemoglobin, full blood cell counts, liver function tests, determination of
adverse events and concomitant medication details, as appropriate.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |